AnorMED accepts Genzyme's Offer of US $13.50 a Share - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AnorMED accepts Genzyme's Offer of US $13.50 a Share


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Langley, BC, Canada (Oct. 10)—AnorMED Inc. (www.anormed.com) has determined that Genzyme’s (Cambridge, MA, www.genzyme.com) US $580 million offer to acquire all outstanding AnorMED shares at US $13.50 a share is a “superior proposal.” The offer is 12.5% more than that offered by Millennium Pharmaceuticals on September 26.

Genzyme will amend its tender offer to increase the price offered from US $8.55 per share to US $13.50 per share and to extend the expiry date to November 1, 2006. Millennium has three business days to make adjustments to its own offer if the company still wishes to pursue purchase of the outstanding shares.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
25%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
36%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here